Shield Therapeutics PLC Grant of share options to the CEO (8095B)
June 06 2023 - 4:10AM
UK Regulatory
TIDMSTX
RNS Number : 8095B
Shield Therapeutics PLC
06 June 2023
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Grant of share options to the Chief Executive Officer
London, UK, 06 June 2023: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Accrufer(R)/ Feraccru(R)
(ferric maltol), announces that on 02 June 2023 it granted share
awards in the form of options over ordinary shares in the capital
of the Company ("Ordinary Shares") under Shield Therapeutics'
Retention and Performance Share Plan ("RPSP").
In accordance with the requirements of the EU Market Abuse
Regulations the following options have been granted to Greg Madison
who is deemed a PDMR:
Name Option Plan Number of Ordinary Shares under Option Vesting Date
Greg Madison RPSP 3,507,548 Vesting occurs annually in three equal tranches
and is not subject to performance conditions
but is subject to Mr Madison remaining in
office as at the date of vesting.
------------ --------------------------------------- ------------------------------------------------
Greg Madison RPSP 3,507,548 Vesting occurs on 02 June 2024 and is not
subject to performance conditions but is
subject
to Mr Madison remaining in office as at the
date of vesting.
------------ --------------------------------------- ------------------------------------------------
Mr Madison currently holds 1,893,039 ordinary shares in the
Company.
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated
with them ("PCA")
a) Name Greg Madison
---------------------------------------- -----------------------------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
---------------------------------------- -----------------------------------------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------------- -----------------------------------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------------------------------------------
a) Name Shield Therapeutics plc
---------------------------------------- -----------------------------------------------------------------------
b) LEI code 213800G74QWY15FC3W71
---------------------------------------- -----------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument Options over new Ordinary Shares
Identification code
ISIN: GB00BYV81293
---------------------------------------- -----------------------------------------------------------------------
b) Nature of the transaction Grant of awards over new Ordinary Shares under the Company's Retention
and Performance Share
Plan.
---------------------------------------- -----------------------------------------------------------------------
c) Price(s) and volumes(s) 2023 RPSP Award Price (GBP) Volume
6.8p 7,015,096
----------
---------------------------------------- -----------------------------------------------------------------------
d) Aggregated information
* Aggregate volume Awards granted over 7,015,096 shares in total
6.8 p exercise price
* Price
---------------------------------------- -----------------------------------------------------------------------
e) Date of the transaction 02 June 2023
---------------------------------------- -----------------------------------------------------------------------
f) Place of the transaction Outside of trading venue
---------------------------------------- -----------------------------------------------------------------------
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Oliver Duckworth +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice
Lane/Nigel Birks +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor) +1 617 429 3548 or jmullaly@lifesciadvisors.com
LifeSci Advisors, LLC
John Mullaly
About Accrufer(R)/Feraccru(R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
action compared to other oral iron therapies and has been shown to
be an efficacious and well-tolerated therapy in a range of clinical
trials. More information about Accrufer(R)/Feraccru(R), including
the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched
Accrufer(R) in the US and Feraccru(R) is commercialized in the UK
and European Union by Norgine B.V., who also have the marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of Accrufer(R) /
Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. in the Republic of Korea, and with KYE
Pharmaceuticals Inc. in Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSSDSUMEDSESM
(END) Dow Jones Newswires
June 06, 2023 05:10 ET (09:10 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024
